The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) of JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by Severity
Timeframe: From Baseline up to approximately 24 months
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
Timeframe: From Baseline up to 28 days